EvoPAR-Prostate01

Section NCT
Category Urogenital tumors
Subcategory Prostatakarzinom
Trial Type First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts The intention of the study is to demonstrate superiority of Saruparib (AZD5305) +physician's choice NHA relative to placebo + physician's choice NHA by assessment ofradiographic progression-free survival (rPFS) in participants with mCSPC.
Description for laymen to demonstrate superiority of Saruparib (AZD5305) +physician's choice NHA relative to placebo + physician's choice NHA
JSON Data { "short_title": "EvoPAR-Prostate01", "data_mode": "900", "data_mode_number": "000002337", "official_title": "A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "first", "ctgov_number": "NCT06120491", "eudract_number": null, "general_contact_email": null, "general_contact_phone": null, "hauptpruefer_dd_name": "Prof. Dr. med. Christian Thomas", "description_laie_de": "\u00dcberlegenheitsnachweis von SARUPARIB + NHA gegen\u00fcber Placebo + NHA", "description_laie_en": "to demonstrate superiority of Saruparib (AZD5305) +physician's choice NHA relative to placebo + physician's choice NHA", "description_expert_de": "Ziel der Studie ist es, die \u00dcberlegenheit von Saruparib (AZD5305) + NHA nach Wahl des Arztes im Vergleich zu Placebo + NHA nach Wahl des Arztes anhand der Bewertung des r\u00f6ntgenologischen progressionsfreien \u00dcberlebens (rPFS) bei Teilnehmern mit mCSPC nachzuweisen.", "description_expert_en": "The intention of the study is to demonstrate superiority of Saruparib (AZD5305) +physician's choice NHA relative to placebo + physician's choice NHA by assessment ofradiographic progression-free survival (rPFS) in participants with mCSPC.", "rechtsgrundlage_value": "AMG", "phase_amg_value": "III", "main_cat_id": 11, "sub_cat_id": 54 }
Settings
Short name 900-000002337